Pneumonia. Treatment and diagnosis.

Pneumonia remains a leading cause of morbidity and mortality despite advances in treatment and therapy. The "Pneumonia: Treatment and Diagnosis" session of the Pittsburgh International Lung Conference examined topics related to improving care of patients with pneumonia. These topics included the process and quality of care for community-acquired pneumonia (CAP), diagnosis and treatment of emerging fungal pathogens, an overview of the strengths and weaknesses of different diagnostic modalities, and an example of how basic science is exploring immunomodulatory strategies for pneumonia treatment. Systematic health care provider and institutional improvements can decrease mortality rates in CAP, particularly in patients with increasingly complex comorbidities. Aspects of current guidelines for the diagnosis and treatment of fungal pneumonia were reviewed through a series of case presentations. Proper treatment of pneumonia hinges on correct pathogen identification but is complicated by the variety of diagnostic assays with variable specificity, sensitivity, and interpretation. In addressing this topic, Dr. Patrick Murray, Ph.D., discussed a range of diagnostic tests for a variety of pathogens and guidelines for their use. In addition to the current state of CAP treatment, Bill (Beibei) Chen, M.D., Ph.D., presented a new potential therapeutic agent called forsythin, an immunomodulatory compound derived from a plant used in traditional Chinese medicine. These topics, ranging from institution-sized policy to interactions at the molecular scale, paint a broad perspective of the efforts against pneumonia.

[1]  L. Ying,et al.  Pulmonary mucormycosis , 2013 .

[2]  K. Rabe,et al.  Phosphodiesterase-4 inhibitor therapy for lung diseases. , 2013, American journal of respiratory and critical care medicine.

[3]  Domenico Spina,et al.  Selective PDE inhibitors as novel treatments for respiratory diseases. , 2012, Current opinion in pharmacology.

[4]  A. Soubani,et al.  Pulmonary aspergillosis: a clinical review , 2011, European Respiratory Review.

[5]  Nina Singh,et al.  Mucormycosis: its contemporary face and management strategies. , 2011, The Lancet. Infectious diseases.

[6]  N. Ampel,et al.  An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. , 2011, American journal of respiratory and critical care medicine.

[7]  A. Limper The changing spectrum of fungal infections in pulmonary and critical care practice: clinical approach to diagnosis. , 2010, Proceedings of the American Thoracic Society.

[8]  P. Batra,et al.  Pulmonary coccidioidomycosis. , 1992, Journal of thoracic imaging.

[9]  Assurance in Medicare,et al.  Medicare: A Strategy for Quality Assurance Volume 1 , 1990 .

[10]  D. Rublee The Quality of Care: How Can It Be Assessed? , 1989 .

[11]  A. Donabedian,et al.  The quality of care. How can it be assessed? , 1988, JAMA.

[12]  G. Smulian,et al.  Pulmonary mucormycosis. , 1987, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[13]  M. Richmond,et al.  Distribution of R Plasmids Among the O-Antigen Types of Escherichia coli Isolated from Various Clinical Sources , 1976, Antimicrobial Agents and Chemotherapy.

[14]  J. Edge Pulmonary histoplasmosis. , 1958, The British journal of tuberculosis and diseases of the chest.